The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of gemcitabine and split-dose cisplatin plus everolimus (RAD001) in patients with advanced urothelial cancer.
 
Wassim Abida
No Relationships to Disclose
 
Matthew I. Milowsky
Research Funding - Astellas Pharma (Inst); BIND Therapeutics (Inst); Dendreon (Inst); Exelixis (Inst); Johnson & Johnson (Inst)
 
Irina Ostrovnaya
No Relationships to Disclose
 
Scott R. Gerst
No Relationships to Disclose
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Merck
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Oncogenex; Onyx
 
Ashley Marie Regazzi
No Relationships to Disclose
 
Asia S. McCoy
No Relationships to Disclose
 
Mariel Elena Boyd
No Relationships to Disclose
 
Dean F. Bajorin
No Relationships to Disclose